The GLP-1 ad wars “Healthy Skepticism” comes weeks after Eli Lilly competitor and Ozempic-maker Novo Nordisk launched a print ...
Once again, Eli Lilly is using Hollywood’s biggest night as a platform to speak out on a hot-button issue in pharma. | Once ...
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...
Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for patients that don't have insurance.
Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.
Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new ...
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Eli Lilly and Co.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback